CYP2 Modulator

PIPE-791 is an orally active, blood-brain barrier-permeable selective antagonist of LPAR1. PIPE-791 inhibits LPA-induced calcium mobilization, collagen expression, histamine release, and the activation of fibroblasts, microglia and macrophages. PIPE-791 induces oligodendrocyte precursor cell differentiation, myelination and remyelination, and increases the number of microglia in the retina of normotensive rats. PIPE-791 protects mature oligodendrocytes from cytokine-induced death, reduces the levels of pulmonary fibrosis markers and alleviates neuroinflammation in preclinical models. PIPE-791 can be used in the research of glaucoma, neuroinflammatory diseases, chronic osteoarthritis pain, idiopathic pulmonary fibrosis and multiple sclerosis.

Chlorzoxazone is a SK-type potassium channel activator. Chlorzoxazone modulates FOXO3 phosphorylation and Aβ. Chlorzoxazone enhances immunosuppression, attenuates vasoconstriction, attenuates cognitive deficits, and improves experimental autoimmune encephalomyelitis.

m-Tolualdehyde (3-Methylbenzaldehyde) is an aldehyde metabolite produced by m-xylene metabolism, and it bidirectionally regulates the CYP 2B1, CYP 2E1, and CYP 4B1 isoenzymes in the respiratory tract of rats. m-Tolualdehyde serves as an oxidation substrate and carbon source for Pseudomonas Pxy, and it can be oxidized to m-toluic acid in an NAD⁺ -dependent manner. m-Tolualdehyde exerts a dose-dependent inhibitory effect on CYP 2B1 and CYP 2E1 in the nasal mucosa and lungs of rats, and a dose-dependent activating effect on pulmonary CYP 4B1. m-Tolualdehyde can form aldehyde-heme adducts with the heme group of cytochrome P450. m-Tolualdehyde can be used in studies related to metabolic enzymes in the respiratory tract of rats.

Chlorzoxazone (Standard) is the analytical standard of Chlorzoxazone. This product is intended for research and analytical applications.

N-Desmethyl-Apalutamide, the major active metabolite of Apalutamide (HY-16060), is a selective competitive inhibitor of androgen receptor. N-Desmethyl-Apalutamide is catalyzed by CYP3A4 and CYP2C8 enzymes. The plasma protein binding rate of N-Desmethyl-Apalutamide reaches 95%, with albumin as the primary binding protein. N-Desmethyl-Apalutamide is suitable for prostate cancer-related research.